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ABSTRACT
Previously we have shown that expression of the deubiquitinating enzyme USP17 
is required for cell proliferation and motility. More recently we reported that USP17 
deubiquitinates RCE1 isoform 2 and thus regulates the processing of ‘CaaX’ motif 
proteins. Here we now show that USP17 expression is induced by epidermal growth 
factor and that USP17 expression is required for clathrin mediated endocytosis of 
epidermal growth factor receptor. In addition, we show that USP17 is required for the 
endocytosis of transferrin, an archetypal substrate for clathrin mediated endocytosis, 
and that USP17 depletion impedes plasma membrane recruitment of the machinery 
required for clathrin mediated endocytosis. Thus, our data reveal that USP17 is 
necessary for epidermal growth factor receptor and transferrin endocytosis via 
clathrin coated pits, indicate this is mediated via the regulation of the recruitment of 
the components of the endocytosis machinery and suggest USP17 may play a general 
role in receptor endocytosis.
INTRODUCTION
Ubiquitin is now recognised as an essential post-
translational modification that can have diverse effects 
on the proteins to which it is conjugated, including 
tagging them for proteasomal or lysosomal degradation, 
facilitating protein-protein interactions, or regulating 
their localisation within the cell [1]. Six families of 
deubiquitinating enzymes consisting of at least 98 
members have now been identified and implicated in the 
regulation of many cellular processes [2]. 
The DUB/ubiquitin specific protease 17 (USP17) 
family of deubiquitinating enzymes were originally 
identified in mice as immediate early genes (DUB-1, 
DUB-1A, DUB-2) induced in response to a range of 
cytokines [3, 4]. Subsequently we demonstrated that 
expression of a human homologue, USP17/DUB-3/
Dub3 (subsequently referred to as USP17), is induced in 
response to both cytokine and chemokine stimulation (IL-
4, IL-6, IL-8, SDF1) [5, 6] and that USP17 expression 
is required for proper G1 to S cell cycle progression [7] 
and chemokine driven (IL-8, SDF1) cell motility [6]. In 
addition, others have shown that USP17 knockdown can 
impede tumour growth [8] and that USP17 expression 
is required to prevent the differentiation of embryonic 
stem cells (ESCs) [9]. Mechanistically, we have shown 
that USP17 regulates the activity of the protease Ras 
converting enzyme 1 (RCE1), which is required for the 
processing of ‘CaaX’ motif proteins such as H-Ras and 
N-Ras [10, 11] and most recently we have shown that this 
is mediated via the deubiquitination and re-localization 
of a novel isoform of RCE1 (RCE1 isoform 2) [12]. In 
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addition, others have identified Cdc25A [8], SDS3 [13], 
RIG-I and Mda5 [14] as potential substrates for USP17. 
Previously, we demonstrated that USP17 expression 
blunts EGFR signaling [11] indicating it has a role in the 
regulation of this pathway. In addition, we have shown that 
several cytokines and chemokines [5, 6] induce USP17 
expression and we decided to examine if this was also 
the case for EGF. A study examining DUB-2A, a murine 
homologue of USP17, had indicated DUB-2A regulated 
the trafficking of colony-stimulating factor 3 receptor 
(CSF3R) to the lysosome and thus its down-regulation 
[15]. This prompted us to examine if USP17 had a similar 
impact on the trafficking of EGFR.
In this study we have now demonstrated that 
USP17 expression is induced in response to EGFR 
engagement and is required for EGFR endocytosis in the 
presence of low, but not high, concentrations of EGF. In 
addition, we have shown that USP17 depletion blocks 
the internalisation of transferrin and its receptor (TfR), 
an archetypal substrate for clathrin mediated endocytosis 
(CME). Furthermore, we demonstrate that in the absence 
of USP17 the plasma membrane recruitment of a number 
of components of the CME machinery is impaired. This 
data indicates that USP17 is required for EGFR and TfR 
endocytosis and that it plays a general role in CME. 
RESULTS 
USP17 is required for EGFR endocytosis
To determine if EGF induced USP17 expression we 
stimulated HeLa cells with EGF (0.32 nM) and observed 
a strong induction of both USP17 mRNA and protein (Fig. 
1A) indicating that USP17 expression was indeed induced 
by EGF and this led us to further probe the role of USP17 
in EGFR signaling. 
FIGURE 1: (a) HeLa cells were starved in serum free medium for 3 hrs prior to incubation with 0.32 nM EGF Alexa Fluor 
555 and mRNA and protein samples were harvested at the time points indicated. USP17 and GAPDH (loading control) mRNA 
were then assessed by RT-PCR. USP17 protein levels were assessed by immunoblotting and tubulin was used as a loading control. (b) 
HeLa cells were transfected as indicated. 72 hrs post transfection mRNA and protein samples were harvested and USP17 mRNA and 
protein levels assessed as above. (c) HeLa cells were transfected with the constructs indicated. 72 hrs post transfection the cells were 
starved in serum free medium for 3 hrs prior to incubation with 0.32 nM EGF Alexa Fluor 555. After 15 min the cells were acid washed, 
fixed and the nuclei were stained with DAPI. EGF Alexa Fluor 555 (red) internalisation was then assessed in brightfield and fluorescent 
images taken using confocal microscopy. The bottom panels are enlarged images of the indicated area in the top panels. Scale bar = 20 
µm. (d) At least 50 cells per condition were blindly scored for three separate experiments based on the presence of EGF Alexa Fluor 555 
internalisation. (e) A549 cells were transfected as indicated and 72 hrs post transfection the cells were starved in serum free medium for 3hrs 
prior to incubation with 0.32nM EGF Alexa Fluor 555. After 10 mins the cells were either acid washed or washed with PBS. Subsequently 
they were fixed and the nuclei were stained with DAPI. EGF Alexa Fluor 555 (red) internalisation was then assessed in brightfield and 
fluorescent images taken using confocal microscopy. The middle panels are enlarged images of the indicated area in the upper panels. Scale 
bar = 25 µm. (f) HeLa cells were transfected as indicated and 72 hrs post transfection the cells were starved in serum free medium for 3 hrs 
prior to incubation with 0.32nM EGF Alexa Fluor 555. After 45 mins the cells were acid washed, fixed and the nuclei were stained with 
DAPI. EGF Alexa Fluor 555 (red) internalisation was then assessed in brightfield and fluorescent images taken using confocal microscopy. 
The lower panels are enlarged images of the indicated area in the upper panels. Scale bar = 10 µm. ** p<0.01
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To probe the role of USP17 in EGFR trafficking, we 
transfected HeLa cells with, either the previously validated 
USP17 specific shRNAs (shRNA1 and shRNA2) (Fig. 1B) 
[6, 7], a scrambled shRNA, or empty vector. We initially 
examined the internalisation of EGF Alexa Fluor 555 
(0.32 nM) to see if any gross mis-localisation was evident. 
Control cells internalised the labeled EGF as expected and 
distinct vesicular structures containing EGF were evident 
(Figure 1C, panels 1-2). However, rather than altering the 
trafficking of EGF, USP17 depletion resulted in the failure 
of up to 80% of these cells to internalise EGF, something 
which was starkly illustrated by its absence when these 
cells were stripped of external EGF using an acid wash 
(Figs 1C panels 3-4, 1D). The same experiments were 
carried out using A549 cells and again, when USP17 was 
depleted, these cells failed to internalise any EGF (Fig. 
1E, middle and right panels). However, if these cells were 
not subjected to an acid wash to strip the external EGF, 
the labeled EGF associated with their plasma membrane 
indicating that, although it was not internalised, it may 
still bind to EGFR (Fig. 1E, upper middle and upper right 
panels). To further confirm these observations were due 
to a loss of internalisation, and not a delay in this process, 
we extended the incubation period with EGF Alexa Fluor 
555 out to 45 minutes and still observed no internalised 
EGF (Fig. 1F).
This indicated that USP17 was necessary for EGF 
entry. However, it could have also been explained by 
USP17 depletion resulting in the trafficking of EGFR 
away from the plasma membrane. Therefore, to investigate 
if USP17 was altering the location of EGFR we examined 
the localisation of EGF, along with EGFR, using an 
anti-EGFR antibody. In control HeLa cells we observed 
EGFR on the plasma membrane prior to stimulation, and 
upon EGF treatment, EGF and EGFR co-localised to 
internal vesicular structures which were more prominent 
after cells were stripped of external EGF using an acid 
wash (Figs 2A, top panels, 2B). In USP17 depleted cells 
we again observed prominent EGFR plasma membrane 
staining (Fig. 2A, bottom left panels). However, when 
EGF was added, both the EGF and EGFR remained at 
the plasma membrane and the EGF was lost upon acid 
wash demonstrating it had failed to enter the cell (Figs 2A, 
bottom middle and bottom right panels, 2B). 
To further determine if the failure of EGFR to 
internalise was due to the loss of EGFR signaling, 
we examined ERK1/2 activation upon EGF treatment 
(Fig. 2C, top panels). ERK1/2 activation was observed 
regardless of the USP17 status indicating USP17 is not 
necessary for EGFR activation. We also examined EGFR 
protein levels and observed that the abundance of EGFR 
was not reduced by USP17 depletion (Fig. 2C, bottom 
FIGURE 2: (a) HeLa cells were transfected as indicated. 72 hrs post transfection the cells were starved in serum free medium for 
3 hrs prior to incubation with 0.32 nM EGF Alexa Fluor 555 where indicated. After 15 min the cells were acid washed, where indicated, 
fixed and the nuclei stained with DAPI. The cells were then stained using an anti-EGFR antibody and EGF Alexa Fluor 555 (red) and 
EGFR (green) internalisation was assessed in brightfield and fluorescent images taken using confocal microscopy. The right panels are 
enlarged images of the indicated area in the left panels. Scale bar = 10 µm. (b) At least 50 cells per condition were blindly scored for three 
separate experiments based on the presence of EGF Alexa Fluor 555 and EGFR co-staining post acid wash. (c) HeLa cells were transfected 
as indicated. 72 hrs post transfection the cells were starved in serum free medium for 3 hrs prior to incubation with 0.32 nM EGF. Whole 
cell lysates were harvested and levels of phosphorylated ERK1/2, ERK1/2, EGFR and tubulin were assessed by immuno-blotting using 
anti-pERK1/2, anti-ERK1/2, anti-EGFR and anti-tubulin antibodies. ** p<0.01
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panels). Taken together, this data clearly highlighted that 
USP17 is required for EGFR internalisation and indicated 
that the induction of USP17 by EGF allows EGFR 
internalisation. 
USP17 is not required for EGFR endocytosis in 
the presence of high EGF concentrations
EGFR internalisation proceeds mainly via CME 
[16], although clathrin independent pathways are also 
thought to be used if high EGF concentrations are present 
[17]. Therefore, to clarify which pathways are influenced 
by USP17 we examined the internalisation of EGFR 
under high EGF conditions. We transfected HeLa cells 
as before and examined the internalisation of EGF Alexa 
Fluor 555 using high EGF concentrations (3.2 nM) (Fig. 
3A). In the presence of high EGF, USP17 depleted cells 
now showed the presence of internalised EGF in vesicular 
structures, although upon acid wash it was evident that 
these vesicles were localised in a peri-nuclear distribution, 
rather than throughout the cell as observed in the control 
cells (Fig. 3A, bottom panels). These observations were 
further confirmed using recombinant EGF (0.32 nM, 3.2 
nM) and examining the localisation of EGFR using an 
anti-EGFR antibody (Fig. 3B). This again illustrated that 
EGFR endocytosis was blocked in cells lacking USP17 
when low EGF concentrations were used (Fig. 3B, middle 
panels), but that high concentrations could overcome this 
block (Fig. 3B, right panels). These observations now 
suggested that USP17 was specifically required for the 
clathrin dependant internalisation of EGFR. 
Transferrin internalisation requires USP17
Our data indicated that USP17 is required for 
clathrin mediated internalisation of EGFR, but it was 
unclear if USP17 played a role specific to EGFR, or if 
it might play a more general role in CME. Therefore, we 
now examined the impact of USP17 depletion upon the 
internalisation of transferrin, a proto-typical substrate 
for CME. HeLa cells were transfected as before and 
the internalisation of transferrin Alexa Fluor 568 was 
examined using confocal microscopy (Figs 4A-D) and 
FACS analysis (Fig. 4E). In both cases there was at least 
an 80% decrease in the number of cells showing the 
presence of internalised transferrin when USP17 was 
depleted indicating it was also required for transferrin 
internalisation (Figs 4B, D-E). Indeed, if the cells were not 
acid washed prior to visualisation, there was a prominent 
halo of transferrin observed around the cells depleted of 
USP17 indicating the transferrin was binding, but failing 
to internalise (Fig. 4A, middle and right panels). 
We next examined the localisation of transferrin 
along with TfR using an anti-TfR antibody. In control 
cells we observed the majority of TfR on internal 
vesicular structures (Fig. 5A, top panels) and upon 
FIGURE 3: (a) HeLa cells were transfected as indicated. 72 hrs post transfection the cells were starved in serum free medium for 
3 hrs prior to incubation with 3.2 nM EGF Alexa Fluor 555. After 15 min the cells were acid washed where indicated, fixed and the nuclei 
stained with DAPI. EGF Alexa Fluor 555 (red) internalisation was assessed in brightfield and fluorescent images taken using confocal 
microscopy. The right hand panels are enlarged images of the indicated area in the left hand panels. Scale bar = 10 µm. (b) HeLa cells were 
transfected with either scrambled shRNA or USP17 shRNA1 and 72 hrs post transfection the cells were starved in serum free medium for 
3hrs prior to incubation with either 0 nM, 0.32 nM or 3.2 nM recombinant EGF. After 15mins the cells were washed, fixed and stained 
using an anti-EGFR antibody. EGFR (green) internalisation was assessed in fluorescent images taken using confocal microscopy. The right 
hand panels are enlarged images of the indicated area in the left hand panels. White arrows point out plasma membrane staining for EGFR. 
Scale bar = 20 µm.
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FIGURE 4: (a) HeLa cells were transfected as indicated. 72 hrs post transfection the cells were starved in serum free medium for 
30 min prior to incubation with 25 µg/ml transferrin Alexa Fluor 568. After 15 min the cells were fixed and the nuclei stained with DAPI. 
The cells were then assessed for transferrin Alexa Fluor 568 (red) internalisation in brightfield and fluorescent images taken using confocal 
microscopy. The bottom panels are enlarged images of the indicated area in the top panels. Scale bar = 25 µm. (b) At least 50 cells per 
condition were blindly scored for three separate experiments based on the presence of transferrin Alexa Fluor 568 on the cell surface. (c) 
HeLa cells were transfected as indicated. 72 hrs post transfection the cells were starved in serum free medium for 30 min prior to incubation 
with 25 µg/ml transferrin Alexa Fluor 568. After 15 min the cells were acid washed, fixed and the nuclei stained with DAPI. The cells were 
then assessed for transferrin Alexa Fluor 568 (red) internalisation in brightfield and fluorescent images taken using confocal microscopy. 
The bottom panels are enlarged images of the indicated area in the top panels. Scale bar = 25 µm. (d) At least 50 cells per condition were 
blindly scored for three separate experiments based on the presence of transferrin Alexa Fluor 568 internalisation. (e) HeLa cells were 
transfected as indicated. 72 hrs post transfection the cells were starved in serum free medium for 30 min prior to incubation with 25 µg/ml 
biotin labeled transferrin (Sigma). After the indicated time points the cells were acid washed, fixed and stained using streptavidin-CY5 (BD 
Biosciences, USA). The cells were then assessed for transferrin internalisation using flow cytometry. * p<0.05, ** p<0.01, *** p<0.001.
FIGURE 5: (a) HeLa cells were transfected as indicated. 72 hrs post transfection the cells were starved in serum free medium for 
30 min prior to incubation with 25 µg/ml transferrin Alexa Fluor 568. After 15 min the cells were fixed and the nuclei stained with DAPI. 
The cells were then stained using an anti-TfR antibody and assessed for transferrin Alexa Fluor 568 (red) and TfR (green) internalisation 
in brightfield and fluorescent images taken using confocal microscopy. The right panels are enlarged images of the indicated area in the 
merged panels. Scale bar = 25 µm. (b) HeLa cells were transfected as indicated and 72 hrs post transfection the cells were starved in serum 
free medium for 3 hrs prior to incubation with 25 µg/ml transferrin Alexa Fluor 568. After 45 mins the cells were acid washed, fixed and 
the nuclei were stained with DAPI. Transferrin Alexa Fluor 568 (red) internalisation was then assessed in brightfield and fluorescent images 
taken using confocal microscopy. The lower panels are enlarged images of the indicated area in the upper panels. Scale bar = 10 µm.
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transferrin treatment we observed transferrin and TfR 
co-localised to these internal vesicular structures (Fig. 
5A, top right panels). In contrast, USP17 depleted cells 
showed prominent TfR staining on the plasma membrane, 
which co-localized with transferrin and suggested TfR 
and transferrin both failed to internalise (Fig. 5A, bottom 
panels). Again, to confirm this was due to an internalisation 
block, and not a delay, we extended the incubation period 
with transferrin out to 45 minutes and still observed no 
internalisation (Fig. 5B). This now indicated that USP17 
plays a more general role in CME as both EGFR (ligand 
triggered endocytosis) and TfR (constitutively recycles) 
require USP17 expression to internalise via CME. 
USP17 depletion impedes plasma membrane 
recruitment of CME machinery
Our work now indicated USP17 had a role in CME, 
but to further explore where USP17 acts, we examined 
the impact of USP17 depletion upon a number of the 
components required for CME. 
Previous studies have indicated that EGF triggers 
clathrin recruitment to the plasma membrane within 1 
minute [18] and we now transfected HeLa cells as before 
and examined clathrin localisation in the presence and 
absence of EGF using an anti-clathrin antibody (Figure 
6A). In control cells, EGF treatment triggered the 
recruitment of clathrin spots to the periphery of the cell 
(Figs 6A, left panels, 6B, 6C). In cells lacking USP17 this 
recruitment was not evident (Figs 6A, middle and right 
panels, 6B, 6C) and treating these cells with EGF had 
no significant impact upon the amount of clathrin at the 
periphery (Fig. 6C). 
We then examined the recruitment of AP-2, using an 
anti-µ2 subunit of AP-2 antibody, and observed that EGF 
again triggered the recruitment of AP-2 to the periphery of 
the cell in control cells (Figs 6D, 6E, 6F). However, this 
recruitment was again significantly reduced when USP17 
was depleted (Figs 6D, 6E, 6F). 
FIGURE 6: (a) HeLa cells were transfected as indicated. 72 hrs post transfection the cells were starved in serum free medium for 3 
hrs prior to incubation with 0.32 nM recombinant EGF where indicated. After 1 min the cells were fixed and stained using an anti-clathrin 
antibody (green) and clathrin localisation was assessed in brightfield and fluorescent images taken using confocal microscopy. Bottom 
panels are enlarged images of the indicated area in the upper panels. Scale bar = 10 µm. (b) At least 50 cells per condition were blindly 
scored for two separate experiments based on the presence of clathrin at the plasma membrane. (c) Quantification of fluorescent signal 
intensity corresponding to endogenous clathrin within region of interest (ROI) defined as 15 pixel wide strip overlapping with boundary 
of the cell (detected in corresponding brightfield images). Intensities of the pixels within the ROI were quantified using Fiji software and 
expressed as mean intensity of ROI. ROIs of at least 10 representative cells for each condition were quantified and plotted. (d) HeLa cells 
were transfected as indicated. 72 hrs post transfection the cells were starved in serum free medium for 3 hrs prior to incubation with 0.32 
nM recombinant EGF where indicated. After 1 min the cells were fixed and stained using an anti-µ2 subunit of AP-2 antibody (green) and 
AP-2 localisation was assessed in brightfield and fluorescent images. Bottom panels are enlarged images of the indicated area in the upper 
panels. Scale bar = 10 µm. (e) At least 50 cells per condition were blindly scored for two separate experiments based on the presence of 
AP-2 at the plasma membrane. (f) Quantification of fluorescent signal intensity corresponding to endogenous AP-2 within region of interest 
(ROI) defined as 15 pixel wide strip overlapping with boundary of the cell (detected in corresponding brightfield images). Intensities of the 
pixels within the ROI were quantified using Fiji software and expressed as mean intensity of ROI. ROIs of at least 8 representative cells for 




) is a lipid 
whose production at the plasma membrane allows the 
recruitment of many of the components of the CME 
machinery [19]. We also looked at the impact of USP17 
knockdown on the localisation of PIP
2
, using an anti-PIP
2
 
antibody, and we observed that USP17 loss resulted in 
a significant reduction in the PIP
2
 observed around the 
periphery of the cell upon EGF treatment (Figs 7A, middle 
and right panels, 7B). A number of enzymes are capable 
of producing PIP
2
 at the plasma membrane, however 
phosphoinositol-5-phosphate kinase beta (PIP5Kβ) has 
previously been shown to be necessary for EGFR and 
TfR endocytosis [20, 21]. Therefore, we looked at the 
localisation of a carboxy terminal FLAG-tagged PIP5Kβ 
and found that USP17 loss also resulted in a significant 
decrease in plasma membrane localisation of PIP5Kβ 
(Figs 7C, middle and right panels, 7D).
Collectively, this data now indicated that USP17 is 
required for CME as it allows the proper recruitment of 
the necessary machinery to the periphery of the cell.
DISCUSSION
The data presented here demonstrates that USP17 
expression is required for the internalisation of both EGF 
and EGFR in the presence of low level, but not high level 
EGF. This indicates that USP17 is required for the clathrin 
dependent internalisation of EGFR, something which is 
further confirmed by the demonstration that USP17 is also 
required for the internalisation of transferrin and TfR, 
archetypal substrates for clathrin mediated internalisation. 
In addition, this data also demonstrates that USP17 
expression is necessary for the localisation of PIP5Kβ to 
the plasma membrane and therefore the production of PIP
2
 
and the resulting recruitment of components of the CME 
machinery such as AP-2 and clathrin itself. In addition, 
when taken in conjunction with our previous observations 
that USP17 expression is induced in response to multiple 
stimuli [5, 6] our observations indicate that USP17 may 
play a fundamental role in regulating the internalisation 
of multiple receptor types and its induction may play a 
pivotal role in the regulation of the internalisation route 
selected. 
This is the first report of a deubiquitinating enzyme 
being required for the internalisation of EGFR. However, 
other deubiquitinating enzymes such as AMSH and USP8 
have previously been implicated in the regulation of 
EGFR endosomal trafficking after its internalisation [22]. 
In particular, EGFR has been shown to be ubiquitinated 
upon activation [23], prior to being internalised and 
trafficked to early endosomes from where it can either 
be recycled or sent to the lysosome for degradation [24]. 
AMSH can deubiquitinate EGFR and prompt recycling 
to the plasma membrane [25], whilst USP8 is required 
for the degradation of EGFR in the lysosome [26, 27, 28, 
29]. AMSH and USP8 also play a similar role in regards 
to ERBB2, ERBB3, hepatocyte growth factor receptor 
(c-met), protease activated receptor 2, the delta-opioid 
receptor (DOR) and the chemokine receptor CXCR4 
[29, 30, 31, 32, 33]. A number of other deubiquitinating 
enzymes have also been implicated in the regulation of 
FIGURE 7: (a) HeLa cells were transfected as indicated. 72 hrs post transfection the cells were starved in serum free medium for 
3 hrs prior to incubation with 0.32 nM recombinant EGF. After 1 min the cells were fixed and stained using an anti-PIP
2
 antibody (green) 
and PIP
2 
localisation was assessed in brightfield and fluorescent images taken using confocal microscopy. Bottom panels are enlarged 
images of the indicated area in the upper panels. Scale bar = 10 µm. (b) At least 50 cells per condition were blindly scored for two separate 
experiments based on the presence of PIP
2 
at the plasma membrane. (c) HeLa cells were transfected as indicated. 72 hrs post transfection the 
cells were starved in serum free medium for 3 hrs prior to incubation with 0.32 nM recombinant EGF. After 1 min the cells were fixed and 
stained using an anti-FLAG antibody (green) and PIP5K beta localisation was assessed in brightfield and fluorescent images. Bottom panels 
are enlarged images of the indicated area in the upper panels. Scale bar = 10 µm. (d) At least 50 cells per condition were blindly scored for 
two separate experiments based on the presence of PIP5K beta at the plasma membrane. * p<0.05, ** p<0.01, *** p<0.001.
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endosomal trafficking [34], but to date this is the first 
report of such an enzyme being required for receptor 
internalisation. 
We knew USP17 impacted upon EGFR signaling 
[11] and its induction by EGF led us to investigate this 
further. Another study indicating DUB-2A could impede 
the trafficking of CSF3R [15] prompted us in particular 
to examine its impact upon EGFR trafficking. However, 
rather than altering trafficking, we observed that USP17 
loss blocked EGF and EGFR internalisation. Although 
unexpected, this fits with our previous observation that 
MEK1/2 and ERK1/2 activation was down-regulated 
upon USP17 over-expression [11] as the loss of EGFR 
internalisation results in enhanced Ras/MEK/ERK 
activation [35, 36]. 
The observation that higher concentrations of EGF 
could allow its internalisation in the absence of USP17 
pointed to a role for USP17 specifically in clathrin 
mediated endocytosis as previous studies have indicated 
whilst EGFR is mainly internalised via a clathrin 
dependent mechanism [16, 37], a clathrin independent 
mechanism can be utilised in the presence of higher 
concentrations of EGF [38]. This was further supported 
by the observation that USP17 depletion blocked the 
recruitment of components of the CME machinery to 
the plasma membrane upon EGF stimulation and that 
transferrin internalisation was also lost upon USP17 
depletion, as transferrin is regarded as a marker of this 
pathway. This impact on clathrin mediated endocytosis 
also potentially fits with our previous observations in 
regards to IL-8 and SDF1. In particular, the receptors 
for IL-8 (CXCR1/2) and SDF1 (CXCR4), like many 
other G-protein coupled receptors, internalise mainly 
via clathrin coated vesicles [39]. In addition, it has 
also been demonstrated that CXCR2 internalisation is 
required for CXCR2 driven chemotaxis [40, 41] with 
mutants of CXCR2 [41], or dynamin [40], which prevent 
internalisation blocking CXCR2 driven chemotaxis. 
Therefore, the previously observed loss of IL-8 and SDF1 
driven chemotaxis in the absence of USP17 [6] would fit 
with the failure of the chemokine receptors to internalise 
upon engagement. In addition, the study examining DUB-
2A [15] only examined DUB-2A over-expression and 
it is possible that the alterations in trafficking observed 
were due to DUB-2A over-expression triggering either 
earlier receptor internalisation, or altering the route 
utilised, and that DUB-2A is similarly required for 
receptor internalisation. Little is known in regards to the 
mechanisms responsible for the internalisation of the IL-4 
and IL-6 receptors and it is difficult to elucidate the role 
of USP17 in these cases. However, it could be speculated 
that the induction of USP17 is again required to allow the 
internalisation and proper function of these receptors as 
both are known to internalise upon ligand engagement [42, 
43].
The observation, that in the absence of USP17, 
the CME machinery doesn’t localise properly to the 
plasma membrane, indicated that USP17 is required to 
allow CME as it allows the localisation of PIP5Kβ to the 
plasma membrane and thus the production of PIP
2
 and the 
recruitment of the CME machinery. Indeed, this would fit 
with our previous work on USP17 as it has been observed 
that Rac1 is required for PIP5Kβ localisation to the plasma 
membrane [44], Rac1, RhoA and Cdc42 activate PIP5K 
family members [45] and previously we have observed 
USP17 depletion blocks Rac1, RhoA and Cdc42 plasma 
membrane localisation [6, 7]. This would suggest that 
USP17 is required for Rac1, and thus PIP5Kβ localisation 
to the plasma membrane and thus CME. This connection 
to Rac1, a ‘CaaX’ motif protein, also suggests that the 
USP17 substrate responsible for this regulation may 
well be RCE1 isoform 2 [12] as it has previously been 
implicated in the processing of ‘CaaX’ motif protein [12]. 
Indeed, we have previously shown that over-expressing 
RCE1 isoform 2 can mimic the impact of USP17 depletion 
upon cell growth [12] indicating it is the USP17 substrate 
responsible for this effect. However, to confirm this is 
indeed the case, further studies will be required. 
USP17 has also previously been shown to be 
necessary for proper cell cycle progression from G1 to 
S-phase and USP17 expression has been shown to be 
regulated in a cyclical fashion throughout the cell cycle 
[7]. It has been proposed that one, or a combination, of the 
previously identified USP17 substrates, RCE1 isoform 2 
[10, 12], Cdc25A [8] or SDS3 [13] were responsible for 
its action upon the cell cycle. However, it has also been 
shown that clathrin mediated endocytosis is lost during 
mitosis [46], in particular during early mitosis [47] with 
clathrin potentially playing alternative roles during this 
period [48]. EGFR endocytosis has also been shown to be 
tightly regulated during the cell cycle and to be clathrin 
independent during M-phase [49]. Our observations could 
indicate regulation of USP17 could potentially contribute 
to the control of CME during the cell cycle and thus the 
regulation of the cell cycle itself.
The data presented here demonstrates that USP17 is 
required for CME of EGF and transferrin. It also indicates 
that USP17 plays a fundamental role in regulating the 
CME of multiple receptors and as such its induction may 
play a pivotal role in the regulation of receptor endocytosis 
and signalling. USP17 has also been suggested to 
represent a potential target for cancer therapy due to its 
over-expression in a number of tumour tissues [7], its 
association with recurrence and metastases in non-small 
cell lung cancer (NSCLC) [50], as well as its necessity 
for cell cycle progression [7], tumour growth [8] and cell 
migration [6]. However, its requirement for EGFR CME 
could make it an even more attractive target as EGFR 
signalling has been suggested to be more sustained when 
it is internalised and recycled via CME [51] and activating 
mutations of EGFR cause the receptor to be preferentially 
recycled back to the plasma membrane [52]. Therefore, 
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inhibition of USP17 could potentially prevent EGFR 
CME, limiting its signalling capacity and driving it to the 
lysosome for destruction. 
MATERIALS AND METHODS
Plasmids
pDQ-EV (His), pDQ-USP17 (His), and pDQ-
USP17CS (His) were kind gifts from Dr. Derek Quinn 
(Queen’s University, Belfast, UK). The pSUPER-
USP17shRNA (USP17 shRNA1; target sequence 
5’-GCAGGAAGATGCCCATGAA-3’), pRS-
USP17shRNA (USP17 shRNA2; target sequence 
5’-GATGATTTGGCTCCTGTGGCAAGACAGCT-3’) 
and pRS-scrambled shRNA were previously described [6]. 
Cell Culture and DNA Transfections
HeLa cells (American Type Culture Collection 
(ATCC), Manassas, USA) were grown in DMEM 
supplemented with 10% FCS, 1% penicillin (10,000 U/ml) 
/streptomycin (10,000 µg/ml), and 1% L-glutamine (200 
mM) (Life Technologies-Gibco, Paisley, UK). Cells lines 
were grown at 37oC in a 5% CO
2
 humidified incubator. 
Cells were transfected with FuGENETM 6 transfection 
reagent (Roche Diagnostics, Indianapolis, USA) according 
to manufacturer’s instructions. Cells were seeded between 
0.5 x 106 and 1.0 x 106 cells for protein experiments or 
0.7-2.5 x 104 on 4-well glass culture slides (BD Falcon, 
Bedford, USA) for microscopy experiments. The cells 
were transfected with 2µg of plasmid DNA for protein 
experiments and biological assays or 0.25 µg of plasmid 
DNA for confocal microscopy experiments. For those 
experiments with EGF stimulation, cells were rested for 
3 hours in DMEM medium without serum. Cells were 
then stimulated with 0.32 nM-3.2 nM EGF Alexa Fluor 
555 (Invitrogen-Molecular Probes, Eugene, USA) or 
recombinant human EGF (Invitrogen-Gibco, Maryland, 
USA) for the indicated times in the figures. 
EGF internalisation
Transfected cells were rested for 3hrs in DMEM 
medium without serum and stimulated with 0.32nM-
3.2nM EGF Alexa Fluor 555 (Invitrogen-Molecular 
Probes, Eugene, USA) or recombinant EGF (Invitrogen-
Gibco, Maryland, USA) for the indicated times in the 
figures. 0.32 nM and 3.2 nM EGF corresponded to the 
low (2 ng/mL) and high (20 ng/mL) EGF concentrations 
previously used [38]. Subsequently, to remove 
extracellular EGF cells were incubated with acid wash 
buffer (50 mM glycine, 150 mM NaCl, pH=3.0) for 5min 
at 37oC and washed with PBS (Life Technologies-Gibco, 
Paisley, UK) prior to fixing.
Transferrin internalisation
Transfected cells were rested for 30 min in DMEM 
medium without serum. Cells were then incubated with 
25 μg of transferrin Alexa Fluor 568 (Invitrogen-Gibco, 
Maryland, USA) for the indicated times in the figures. 
Extracellular Tf was removed as previously described for 
EGF internalization.
Confocal Microscopy
HeLa and A549 cells were seeded at 0.7-2.5x104 
cells/1.7 cm2 well of glass culture slides (BD Falcon, 
Bedford, USA). Cells were transfected as previously 
described. The cells were fixed in 4% parafomaldehyde 
(Sigma-Aldrich, Steinheim, Germany), in PBS for 20 min. 
The cells were then permeabilized in 0.5% Triton X-100 
in PBS for 5 min, washed in PBS and blocked in blocking 
solution (1% BSA, 10% donkey serum [both from Sigma, 
St. Louis, USA] in PBS) for 1 h at RT. Transfected 
proteins and cell organelles were stained with appropriate 
antibodies or counter stains according to manufacturer’s 
protocol. Antibodies and co-stains were as follows: 
mouse anti-EGFR (GR01L, 1:1000, Merck-Calbiochem, 
Darmstadt, Germany), mouse anti-transferrin receptor 
(1:100, Invitrogen, Camarillo, USA), mouse anti-clathrin 
(1:300, Abcam, Cambridge, UK), mouse anti-AP-50 
(1:200, BD Transduction Labs, USA), mouse anti-PIP
2 
(1:200, Enzo Life Sciences, New York, USA), mouse-
anti-FLAG FITC (1:100, Sigma, St. Louis, USA), donkey 
anti-mouse Alexa Fluor 488 and donkey anti-rabbit Alexa 
Fluor 568 (both 1:200, Invitrogen-Molecular Probes, 
Eugene, USA). The slides were sealed with a coverslip 
and Prolong Gold antifade mounting media with DAPI 
(Life Technologies-Molecular Probes, Eugene, USA). 
Slides were viewed on a Leica SP5 Confocal Microscope. 
Fluorescent images were captured with a 63x lens zoomed 
1-4x with a 1024x1024 frame and 400 Hz scanning speed. 
Images were analyzed using Leica LAS AF software. The 
images presented in the same figures were captured using 
standardized setting and exposure times. 
RNA extraction and reverse transcription-PCR
RNA was extracted using STAT-60 according to the 
manufacturer’s instructions (Tel-Test Inc, Friendswood, 
USA). Reverse transcription-PCR (RT-PCR) was 
performed on 1 μg of total RNA using ImProm-II Reverse 
Transcription System (Promega, Madison, USA) as 
described previously [7]. The following primers were 




CACAAGCATAGCCCTC-3′ (reverse). GAPDH 
5’-ATGGCAAATTCCATGGCA-3’ (forward) 
5’-TCTAGACGGCAGGTCAGG-3’ (reverse). 
Cell Lysis and Immunoblotting
Cells were lysed in the following buffer: 25 
mM TrisHCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS, supplemented with 
phenylmethylsulphonyl fluoride (1 mM), aprotinin (1.7 
μg/ml) and leupeptin (10 μg/ml). Lysates were left on 
ice for 20 mins, centrifuged at 15,000 x g for 10 min at 
4 oC. Equal volumes of whole cell lysate were added to 
Laemlli buffer to a final concentration of 1X with 5% 
β-mercaptoethanol (Sigma, Germany). The samples 
were boiled for 5 min at 99oC for protein denaturation. 
The samples were analyzed by SDS-PAGE and Western 
blotting on PVDF membrane (Millipore, Waterford, UK). 
The membranes were then blocked in appropriate blocking 
agent, either 5% marvel or 3% BSA, in 0.1% Tween-20/
PBS for 1 h. After blocking, the membranes were probed 
with the indicated antibodies for 1 hr at RT or overnight at 
4 oC. The following primary antibodies were used: rat anti-
tubulin (1:10000, Abcam, Cambridge, UK), mouse anti-
pERK1/2, mouse anti-ERK (both 1:1000, Cell Signalling, 
Danvers, USA), mouse anti-USP17 (Fusion Antibodies, 
Belfast, UK), mouse anti-EGFR (BD Biosciences, USA). 
The membrane was incubated with the appropriate 
secondary antibody: either goat anti-mouse HRP conjugate 
or goat anti-rabbit HRP conjugate (both diluted 1:10,000, 
BioRad, Hertfordshire, UK) or rabbit anti-rat HRP 
conjugate (1:40,000, Abcam, Cambridge,UK). Proteins 
were detected with a chemiluminescence protocol and 
were exposed using the ChemiDoc XRS+ imaging system 
(BioRad, Hercules, USA).
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